Showing results (1-10 of 29) with videos related to
Sort By:
Pageof 3
Cancers|October 16, 2025
Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: A Review of Pathogenesis, Diagnosis and ManagementAbarajithan Chandrasekaran, Justin C MoserDrugs|February 26, 2020
Mechanisms of Resistance to PD-1 Checkpoint BlockadeJustin C Moser, Siwen Hu-LieskovanSeminars in Cutaneous Medicine and Surgery|July 25, 2018
Adjuvant therapy for resected high-risk melanomaJustin C Moser, Kenneth F GrossmanActa Oncologica (Stockholm, Sweden)|July 2, 2020
Characterization of uveal melanoma clinical trial design: a systematic review to establish an elusive standard of careHarrison G Zhang, Justin C Moser, Lauren A DalvinCurrent Opinion in Ophthalmology|February 19, 2021
Uveal melanoma: laboratory advances and new frontiers in patient careTimothy T Xu, Justin C Moser, Lauren A DalvinCase Reports in Dermatology|June 29, 2023
Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant PatientMax Miller, Nancy H Kim, Maya K Thosani, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2020
Biomarkers in Precision Cancer Immunotherapy: Promise and ChallengesWilliam B McKean, Justin C Moser, David Rimm, et al.Cornea|February 2, 2023
BRAF Immunohistochemical Studies of Pediatric Conjunctival LesionsKelsey Chen, Kerri McInnis-Smith, Nishant Tiwari, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 20, 2020
Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodiesKelsey Baron, Justin C Moser, Shiven Patel, et al.Acta Oncologica (Stockholm, Sweden)|January 11, 2020
Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanomaJustin C Moser, Guo Wei, Sarah V Colonna, et al.Pageof 3